https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36361 Wed 24 May 2023 12:19:20 AEST ]]> Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21794 9 months or TTBF > 3 years. Conclusion: TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.]]> Wed 11 Apr 2018 15:10:15 AEST ]]> A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24716 Wed 11 Apr 2018 14:27:57 AEST ]]> Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42275 Tue 07 Nov 2023 11:20:11 AEDT ]]> Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7893 Sat 24 Mar 2018 10:44:59 AEDT ]]> Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7789 Sat 24 Mar 2018 08:39:20 AEDT ]]> Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7041 Sat 24 Mar 2018 08:37:55 AEDT ]]> Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21389 Sat 24 Mar 2018 08:05:04 AEDT ]]> Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18127 Sat 24 Mar 2018 08:04:29 AEDT ]]> FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21357 Sat 24 Mar 2018 07:51:27 AEDT ]]> Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5594 Sat 24 Mar 2018 07:49:21 AEDT ]]> FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part II post-radical prostatectomy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28752 Sat 24 Mar 2018 07:37:36 AEDT ]]> Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33247 7 cutpoint identified in 2014 for the BP and STI endpoints. A tertiary objective of the trial is to determine whether intercurrent medical conditions will impact independently on delayed radiotherapy morbidity and other treatment related morbidity.]]> Mon 23 Sep 2019 13:37:53 AEST ]]>